Bennett C, Woo W, Bloch M, Cheung K, et al. Immunogenicity and safety of a bivalent (omicron BA.5 plus ancestral) SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose: interim analysis of a phase 3, non-inferiority, randomised, clinical trial. Lancet Infect Dis 2024 Mar 6:S1473-3099(24)00077.
PMID: 38460525